Exploring Treatment Options for NSCLC
Released On
May 31, 2023
Expires On
May 31, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology, Primary Care, Pulmonology
Topic(s)
Lung Cancer
This activity is provided by AKH Inc., Advancing Knowledge in Healthcare.
This activity is supported in part by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour
- Physician Assistants — 1.0 AAPA Category 1 credit
- Nurse Practitioners — 1.0 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed for an audience of community-based medical and surgical oncologists as well as oncology nurses and advanced practice nurses who manage patients with non-small-cell lung cancer.
Program Overview
In this activity, you will learn how to choose an ideal treatment protocol and individualize care for patients with non-small-cell lung cancer (NSCLC) undergoing treatment. Virtual patient simulation technology will be used to create a virtual, yet realistic, environment where you will deliver care to multiple patients, receive feedback regarding your clinical approach, and observe the direct impact of your clinical decisions on patient outcomes. After completing this activity, you will have the knowledge and strategies needed to apply new patient care strategies that are based on evidence-based recommendations, current data, and patient experience.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Choose an ideal treatment protocol (immune checkpoint inhibition alone, as dual therapy or in combination with chemotherapy) based on workup findings, pathologic profiling, and safety and efficacy data
- Apply knowledge of the patient experience, psychosocial needs, and disparities to individualize care for NSCLC patients undergoing treatment
Faculty
Sandip P Patel, MD
Institution: UC San Diego Moores Cancer Center
Specialization/Interest Area(s): Medical Oncology, Immunotherapy, Thoracic Oncology, Phase 1 Clinical Trials, Solid Tumor Cellular Therapy, Biomarkers, Computational Immunopathology
Bio: Sandip Patel, MD is a Professor at UCSD and a Medical Oncologist focusing on early phase clinical trials of immunotherapy and thoracic oncology. He is the leader for the Experimental Therapeutics (Phase 1) Program and Deputy Director for the Center for Precision Immunotherapy at UCSD. He is co-leader of the NRG Developmental Therapeutics Committee and co-leader of the University of California Lung Cancer Consortium.
Accreditation Statement
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Credit being awarded: 1 ANCC contact hours.
Physician Assistants
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 5/31/2024. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners Continuing Education
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1 contact hour(s) (which includes 0 hour(s) of pharmacology).
Disclosures of Conflicts of Interest
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
- Sandip Patel, MD
- Advisor: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Rakuten, Tempus
- Dorothy Caputo, MA, BSN, RN
VP, Healthcare Continuing Education and Operations - Nothing to disclose
- Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer)
- Nothing to disclose
- AKH Inc Staff and Planners
- Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.
Contact Information
For CME questions please contact: Wendi@akhcme.com.